Delcath Systems (NASDAQ:DCTH) Stock, Quote.Headers.trade-ideas

Delcath Systems

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

jim cramer chart shutter

Long Ideas

News

Markets

Media

Trading Ideas

ADMA

DCTH

&#34;Mad Money&#34; host Jim Cramer said, &#34;Any time there&#39;s immunity-compromised patients, there&#39;s some big money down the road.&#34;

&#39;This Is A Very Speculative Situation,&#39; Jim Cramer On ADMA Biologics

Wall street sign in New York

Equities

Government

Large Cap

Macro Economic Events

Macro Notification

Market Summary

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Currency ETFs

Forex

Global

Econ #s

Economics

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ONON

PLUG

PODD

SPWR

PowerShares DB US Dollar Index Bullish Fund

XLRE

Wall Street is experiencing a subdued trading session, with all major indices showing minimal movement around midday in New York.

Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What&#39;s Driving Markets Tuesday?

alibaba_logo

Intraday Update

Movers

AGYS

AKYA

AUGX

BABA

BETR

BIOL

BYND

CLOV

CTNT

DWSN

EAST

FENC

FFIE

FOSL

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

INVO

JAMF

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MBIN

NOTV

NOVA

PSFE

RENT

SCPX

SHIM

SMRT

Sony Group Corporation American Depositary Shares

SONY

SPCE

STNE

SYRA

TLRY

UXIN

VUZI

WOOF

WULF

Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Delcath Systems Inc

Biotech

General

Delcath Systems Highlights Presentation Of Data At ESMO 2024 Demonstrating Efficacy Of HEPZATO KIT For Metastatic Uveal Melanoma Subgroups

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said, &#8220;This is a very speculative situation,&#8221; when asked about ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>). &#8220;Any time there's immunity-compromised patients, there's some <a href="https://www.benzinga.com/quote/ADMA">big money down the road,&#8221; he added.</a>
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates. 
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
&#8220;This is one of those situations that is very difficult,&#8221; Cramer on MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>). &#8220;If they don't pull out of the tailspin of losses, then it just doesn't matter.&#8221;
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
When asked about Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), he said, &#8220;There's no investing. At this point, it is speculating.&#8221;
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
Price Action:
<ul>
<li>ADMA Biologics shares fell 0.1% to settle at $17.22 on Thursday.</li>
<li>MP Materials shares gained 3.2% to close at $12.90.</li>
<li>Delcath Systems shares gained 1.2% to close at $10.77.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics

Delcath Systems Announces Results from Independent Study On Liver-Directed Therapy for Uveal Melanoma Patients

WIIM

Delcath Systems shares are trading higher after the company published a study by investigators in the Annals Of Surgical Oncology.

Key Findings from the Study:
<ul>
<li>Overall Survival (OS): The study reported median OS of 22.4 months for patients treated with HEPZATO KIT as a first-line therapy (N=17) and 18.4 months as a second-line therapy (N=6).</li>
<li>Hepatic Progression-Free Survival (hPFS): Patients receiving HEPZATO KIT as first-line therapy had a median hPFS of 17.6 months (N=17), compared to 8.8 months (N=6) for immunotherapy and 9.2 months (N=7) for other liver-directed therapies. When used as a second-line therapy, HEPZATO KIT resulted in a median hPFS that was not reached (N=6), showing better outcomes than immunotherapy (14.7 months, N=5) and other liver-directed therapies (7.5 months, N=3) in this patient cohort.</li>
<li>Progression-Free Survival (PFS): The median overall PFS was 15.4 months (N=17) for patients receiving HEPZATO KIT as first-line therapy, compared to 8.8 months (N=6) for immunotherapy and 9.2 months (N=7) for other liver-directed therapies. In the second-line setting, HEPZATO KIT resulted in a median PFS of 22.2 months (N=6), compared to 14.7 months (N=5) for immunotherapy and 7.5 months (N=3) for other liver-directed therapies, reflecting longer disease control in this group.</li>
</ul>

Delcath Systems Publishes Retrospective Study By Independent Investigators In The Annals Of Surgical Oncology. The Study, Titled "Hepatic And Overall Progression-free Survival After Percutaneous Hepatic Perfusion (PHP) As First-line Or Second-line Therapy For Metastatic Uveal Melanoma,"

Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) ("Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the European Society for Medical Oncology journal of Gastrointestinal Oncology. The study, titled "Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation," highlights the efficacy and safety of repeated chemosaturation treatments using Delcath's CHEMOSAT&#xAE; Hepatic Delivery System.
Key Findings from the Independent Study:
<ul>
<li>Patient Population: This retrospective study evaluated the efficacy of CHEMOSAT in 33 previously treated patients with unresectable intrahepatic metastases from various cancers: uveal melanoma (N=19), cholangiocarcinoma (N=8), hepatocellular carcinoma (N=2), and one patient each with ciliary body melanoma, acinar cell carcinoma, pancreatic cancer, or tonsil cancer (N=4). In addition to hepatic metastases, 7 out of 33 patients also had limited extrahepatic disease, which was found not to significantly impact overall survival.</li>
<li>Disease Control Rate: The study reported a disease control rate (DCR) of 91%, with 30 out of 33 patients experiencing either objective tumor response or stable disease. Notably, 6 patients (18.2%) achieved complete response (CR) in the liver, including 5 patients with uveal melanoma and 1 patient with cholangiocarcinoma, who received a median of 5 treatment cycles.</li>
<li>Hepatic Progression-Free Survival: Median hepatic progression-free survival (hPFS) was 52 weeks across all patients, with particularly strong outcomes for specific cancers:
<ul>
<li>69 weeks (16 months) median hPFS in patients with uveal melanoma.</li>
<li>38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma.</li>
</ul>
</li>
<li>Importance of Repeated Treatments: The investigators' approach of using CHEMOSAT in the form of regularly repeated treatment cycles as clinically indicated (Figure 1), similar to systemic chemotherapy, resulted in long-term disease control in the majority of patients and was well tolerated.</li>
<li>Tolerability and Safety: The safety profile of CHEMOSAT was consistent with published literature. Most patients experienced transient hematological adverse events, which were routinely managed with supportive care. Importantly, no significant liver damage was reported, even in patients who underwent multiple treatment cycles. Treatment was discontinued in 2 patients due to adverse events, and 2 patients withdrew consent during the treatment period.</li>
</ul>

Delcath Systems Announces Publication Of An Independent Study Conducted By Investigators At The University Hospital Of Leipzig, Germany, Titled "Hepatic Chemosaturation With Melphalan In Patients With Primary Or Secondary Liver Tumors With Or Without Extrahepatic Tumor Manifestation,"

Stephens &amp; Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Overweight and maintains $25 price target.

Price Target

Reiteration

Analyst Ratings

Stephens & Co. Reiterates Overweight on Delcath Systems, Maintains $25 Price Target

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.75, a high estimate of $25.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 3.57% from the previous average price target of $21.00.
<img src="https://www.benzinga.com/files/images/story/2024/1722945615_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Delcath Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$25.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Delcath Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Delcath Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Delcath Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Delcath Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DCTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delcath Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Delcath Systems: A Closer Look</h2>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Delcath Systems: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Delcath Systems displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 425.8%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Delcath Systems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -353.97%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -73.11%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -29.74%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Delcath Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Delcath Systems: Insights From 4 Financial Analysts

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $22 price target.

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $22 Price Target

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.36) by 33.33 percent. This is a 17.24 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $7.766 million which beat the analyst consensus estimate of $5.226 million by 48.59 percent. This is a 1.47K percent increase over sales of $495.000 thousand the same period last year.

Earnings

Earnings Beats

Earnings Misses

Delcath Systems Q2 2024 GAAP EPS $(0.48) Misses $(0.36) Estimate, Sales $7.766M Beat $5.226M Estimate

Delcath Systems Granted NTAP Status For HEPZATO KIT By CMS, Effective October 1, 2024

Delcath Systems shares are trading higher after Craig-Hallum initiated coverage on the stock with a Buy rating and an $18 price target.

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy rating and announces Price Target of $18.

Initiation

Craig-Hallum Initiates Coverage On Delcath Systems with Buy Rating, Announces Price Target of $18

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and raises the price target from $20 to $22.

HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $22

Wall Street is experiencing a subdued trading session, with all major indices showing minimal movement around midday in New York. The latest producer inflation data provided mixed signals ahead of the highly anticipated consumer <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38790019/april-inflation-data-preview-why-analysts-expect-economic-pressure-to-cool">inflation report on Wednesday.</a>
Fed Chair Jerome Powell reiterated his outlook that U.S. monetary policy will maintain its current rate for a longer period than previously anticipated, dismissing fears <a href="https://www.benzinga.com/markets/equities/24/05/38821976/fed-chair-powell-signals-patience-in-rate-policy-labels-producer-inflation-data-as-mixed">of new rate hikes.</a>
President Joe Biden announced significant tariffs on Chinese imports, imposing 25% on steel and aluminum, 100% on electric vehicles made in China, 25% on EV batteries,<a href="https://www.benzinga.com/markets/asia/24/05/38824198/biden-announces-massive-tariffs-on-chinese-imports-to-protect-us-industries-clean-energy-solar-stock"> and a 50% tariff on semiconductors from China</a>.
The U.S. dollar index (DXY), the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), fell 0.2% negatively reacting to producer inflation readings and Powell&#8217;s remarks. 
Treasury yields slightly softened, with traders holding expectations of two Fed rate cuts by year-end.
All major indices such as the S&amp;P 500, the Dow Jones Industrial Average and the Nasdaq 100 traded broadly flat for the day.
Small caps, as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), rallied 0.8%, on track to notch the highest close since early April. 
Momentum on meme stocks continued to remain wild, with shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) and AMC Entertainment Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) up 22% and 18%, respectively. 
In the commodities market, gold rose 0.8% while oil prices fell 1.4% on concerns that some OPEC+ members want to raise output.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 2.5% to $61,400. 
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,082.41</td>
<td>0.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,200.03</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,393.40</td>
<td>-0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,215.80</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated as of 1:12 p.m. EDT</figcaption></figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was flat at $520.94, the&nbsp;SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was flat at $394.37 and the tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up 0.1% to $443.41, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
Sector-wise, the Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 0.5%. The Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) was the major laggard, down 0.6%.
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>Shares of Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) were up by 4.6% on Tuesday, even though short-seller Blue Orca Capital announced it had taken a short position in the company&#8217;s stock.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) soared over 20% following the announcement that it secured a $1.66 billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38822667/plug-power-analyst-says-loan-commitment-de-risks-hydrogen-stock">government loan to support its clean hydrogen projects,</a> leading to the stock&#8217;s most significant single-day gain in seven years.</li>
<li>SunPower Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) rallied 44%, buoyed by the meme-stock frenzy. </li>
<li>Delcath Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) rose over 30% in reaction to the company&#8217;s quarterly results. </li>
<li>Other stocks reacting to earnings were Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), down 1.1%; On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>), up 18%; International Game Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) up 2.5% and Navios Maritime Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMM#NYSE">NMM</a>) down 6%.</li>
</ul>
Read Now: <a href="https://www.benzinga.com/markets/equities/24/05/38820970/expect-rate-cuts-not-a-recession-fund-managers-most-bullish-on-stocks-in-over-2-years">Expect Rate Cuts, Not Recession: Fund Managers Most Bullish On Stocks In Over 2 Years</a>
Photo: Shutterstock

Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?

Shares of Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) fell sharply during Tuesday's session following mix<a href="https://www.benzinga.com/news/earnings/24/05/38814985/alibaba-stock-dips-as-huge-investment-losses-in-q4-overshadow-revenue-growth-and-dividend">ed first-quarter financial results.</a>
The e-commerce giant reported fiscal fourth-quarter 2023 revenue growth of 7% year-on-year to $30.73 billion, beating the analyst consensus estimate of $30.40 billion. Adjusted earnings per ADS of $1.40 missed the analyst consensus estimate of $1.41, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Alibaba Group shares tumbled 6.8% to $78.86 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares jumped 352.4% to $5.34 as the company reported pricing of $8.19 million follow-on public offering.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) jumped 136% to $0.1434 after jumping over 32% on Monday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares gained 73% to $3.4499 after gaining around 18% on Monday.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares gained 72.1% to $8.93 after surging 78% on Monday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) gained 61.7% to $49.24 after jumping over 74% on Monday.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) rose 62% to $4.4590 as high short-interest stocks gain amid the return of trader "Roaring Kitty" to social media. Additionally, the Biden administration raised tariffs on Chinese solar panels.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) gained 52.5% to $3.7693.</li>
<li>Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) gained 39.7% to $5.18.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) jumped 35% to $3.9165 after the company received a conditional commitment for an up to $1.66 billion loan guarantee from the Department of Energy.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) gained 31.5% to $1.3701 as high-short interest stocks gain amid the return of trader &#8216;Roaring Kitty&#8217; to social media.</li>
<li>Vuzix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) jumped 29.7% to $1.74.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) jumped 29.3% to $15.61 after the company reported first quarter financial results.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) rose 27.6% to $1.6950 after the company that it is a subcontracts for LUKE on a 10-year $43 billion Defense Health Agency contract.</li>
<li>Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) rose 27% to $10.14 after retail investor Roaring Kitty made a return to social media on Monday via a post on X.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) gained 25.5% to $6.80 following upbeat quarterly results.</li>
<li>Tupperware Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) jumped 25% to $2.20 after retail investor Roaring Kitty made a return to social media on Monday via a post on X.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) gained 23.8% to $5.14 after the Biden administration raised tariffs on Chinese solar panels.</li>
<li>Paysafe Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) gained 23.6% to $19.37 as the company posted better-than-expected results for its first quarter.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) gained 24.4% to $4.5191.</li>
<li>Hertz Global Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NYSE">HTZ</a>) rose 19.7% to $6.55.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) gained 18.4% to $3.67 after adding around 7% on Monday.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) rose 17.5% to $2.82 after Land &amp; Buildings sent a letter to the Board urging the exploration of strategic alternatives.</li>
<li>Fossil Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) rose 17.4% to $1.2101.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) gained 16.7% to $3.61 after retail investor Roaring Kitty made a return to social media on Monday via a post on X.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) rose 16.6% to $3.78.</li>
<li>Dawson Geophysical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWSN#NASDAQ">DWSN</a>) jumped 15.8% to $1.68 following first-quarter results.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) rose 15.4% to $6.08.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 15% to $1.04.</li>
<li>On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) gained 14.7% to $35.21 after the company reported better-than-expected first-quarter financial results.</li>
<li>Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) gained 14.5% to $91.89 after the company reported better-than-expected quarterly financial results.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) gained 11.6% to $1.9983.</li>
<li>Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) gained 9.6% to $88.47 following better-than-expected first-quarter earnings.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares rose 9.6% to $2.18.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) gained 9.5% to $12.65.</li>
<li>Rent the Runway, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) shares rose 7.4% to $21.45 after gaining over 12% on Monday.</li>
<li>Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) gained 6.3% to $80.95 after the company reported better-than-expected quarterly financial results</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NASDAQ">SCPX</a>) fell 54.8% to $0.0820 after the company reported pricing of public offering.</li>
<li>Augmedix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) shares fell 50.7% to $1.1596 after the company reported first-quarter financial results.</li>
<li>Inotiv, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) fell 46.8% to $2.22 after Jefferies downgraded the stock from Buy to Hold and lowered its price target from $11.5 to $3.75.</li>
<li>Akoya Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) fell 28.3% to $2.9550 after the company reported worse-than-expected first-quarter financial results and lowered its FY24 revenue forecast.</li>
<li>Eastside Distilling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) dipped 26% to $1.0950 following first-quarter earnings.</li>
<li>JanOne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) fell 23.8% to $2.9443.</li>
<li>Shimmick Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) declined 23.6% to $2.78 following weak quarterly earnings.</li>
<li>Fennec Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) fell 23.2% to $7.70 following quarterly results.</li>
<li>BIOLASE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) shares fell 15.3% to $0.1532 after the company reported mixed first-quarter financial results.</li>
<li>IHS Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) declined 15.2% to $3.2650 following first-quarter results.</li>
<li>Jamf Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) fell 12.1% to $17.95 after the company announced the pricing of a secondary offering by selling stockholders.</li>
<li>Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) declined 10.7% to $42.51 after the company priced a 2.4 million share offering at $43 per share.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares fell 9.8% to $1.10 after jumping over 20% on Monday.</li>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) shares declined 9.6% to $15.04 after the company reported first-quarter financial results.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) shares fell 9.4% to $2.03 after the company reported downbeat results for its first quarter on Monday.</li>
<li>Better Home &amp; Finance Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) declined 7.1% to $0.4135 following first-quarter results.</li>
<li>VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) fell 6% to $4.29.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38815957/planet-fitness-to-rally-around-19-here-are-10-top-analyst-forecasts-for-tuesday">Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Delcath Systems shares are trading higher after the company reported better-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock rose 32.64% to $16.01. The company's market cap stands at $566.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares moved upwards by 26.29% to $3.89. The company's market cap stands at $248.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock rose 25.14% to $1.09. The market value of their outstanding shares is at $1.0 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) stock moved upwards by 22.02% to $2.35. The company's market cap stands at $641.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) stock rose 20.77% to $3.43. The market value of their outstanding shares is at $228.0 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock declined by 52.1% to $0.09 during Tuesday's regular session. The company's market cap stands at $3.1 million. </li>
<li>Augmedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) shares declined by 50.0% to $1.17. The market value of their outstanding shares is at $57.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock declined by 48.09% to $2.17. The company's market cap stands at $55.8 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock decreased by 31.44% to $2.83. The company's market cap stands at $139.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 18.1% to $2.49. The company's market cap stands at $2.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock declined by 16.81% to $0.15. The market value of their outstanding shares is at $5.0 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GBIO

PACB

PROK

SBFM

VRPX

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks were higher, with the Dow Jones gaining around 20 points on Tuesday.
Shares of Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/05/38814383/sony-surpasses-expectations-with-strong-q4-sales-plans-stock-split-and-stock-buyback">quarterly financial results</a>.
Sony Group reported fiscal fourth-quarter 2023 sales growth of 14% year-on-year to $23.49 billion (3.48 trillion Japanese yen), beating the analyst consensus estimate of $19.20 billion. EPS of $1.04 (153.60 yen) beat the analyst consensus estimate of 79 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Sony Group shares gained 6.3% to $80.95 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares rose 72.1% to $8.93 after surging 78% on Monday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares jumped 61.7% to $49.24 after retail investor Roaring Kitty made a return to social media on Monday via a post on X. The company's stock jumped over 74% on Monday.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) gained 62% to $4.4590 as high short-interest stocks gain amid the return of trader "Roaring Kitty" to social media. Additionally, the Biden administration raised tariffs on Chinese solar panels.</li>
<li>Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) shares rose 39.7% to $5.18.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares gained 35% to $3.9165 after the company received a conditional commitment for an up to $1.66 billion loan guarantee from the Department of Energy.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) gained 33% to $6.48.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares rose 29.3% to $15.61 after the company reported first quarter financial results.</li>
<li>Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) jumped 27% to $10.14 after retail investor Roaring Kitty made a return to social media on Monday via a post on X.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) surged 25.5% to $6.80 following upbeat quarterly results.</li>
<li>Tupperware Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) surged 25% to $2.20 after retail investor Roaring Kitty made a return to social media on Monday via a post on X.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) climbed 24.4% to $4.5191.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) rose 23.8% to $5.14 after the Biden administration raised tariffs on Chinese solar panels.</li>
<li>Paysafe Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) gained 23.6% to $19.37 as the company posted better-than-expected results for its first quarter.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) gained 23% to $2.3750 amid a renewed surge in the space after popular retail trader &#8216;Roaring Kitty&#8217; returned to social media.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 22.5% to $0.8745.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) gained 20.6% to $1.2550 as high-short interest stocks gain amid the return of trader &#8216;Roaring Kitty&#8217; to social media.</li>
<li>Hertz Global Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NYSE">HTZ</a>) climbed 19.7% to $6.55.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) gained 17.5% to $2.82 after Land &amp; Buildings sent a letter to the Board urging the exploration of strategic alternatives.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) climbed 16.7% to $3.61 after retail investor Roaring Kitty made a return to social media on Monday via a post on X.</li>
<li>On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) rose 14.7% to $35.21 after the company reported better-than-expected first-quarter financial results.</li>
<li>Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) rose 14.5% to $91.89 after the company reported better-than-expected quarterly financial results.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) gained 11.3% to $3.1220.</li>
<li>Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) rose 9.6% to $88.47 following better-than-expected first-quarter earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 9.5% to $12.65.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 8.8% to $10.32. Recursion Pharmaceuticals recently announced the completion of BioHive-2.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 8.7% to $18.36. Roaring Kitty&#8217;s return may prompt retail investors to use the platform at a higher volume.</li>
<li>Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) rose 8.4% to $36.62.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) gained 7.5% to $17.58. Benchmark analyst Subash Chandra reiterated MP Materials with a Buy and maintained a $30 price target.</li>
<li>Rent the Runway, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) shares gained 7.4% to $21.45 after gaining over 12% on Monday.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) rose 7.3% to $5.42.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) gained 6.1% to $6.39.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 6% to $63.79.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38815957/planet-fitness-to-rally-around-19-here-are-10-top-analyst-forecasts-for-tuesday">Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

BHVN

FCEL

HOOD

JBLU

JOBY

LCID

ROKU

RXRX

Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday

Delcath Systems Q1 2024 GAAP EPS $(0.45) Beats $(0.47) Estimate, Sales $3.139M Beat $2.187M Estimate

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Delcath Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/dcth-stock-quote/">DCTH</a>) just reported results for the second quarter of 2024.<ul><li>Delcath Systems reported earnings per share of -48 cents. This was below the analyst estimate for EPS of -36 cents.</li><li>The company reported revenue of $7.77 million.</li><li>This was 48.49% better than the analyst estimate for revenue of $5.23 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/dcth-stock-earnings-delcath-systems-for-q2-of-2024/">DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024

Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Delcath Systems (DCTH – Research Report) today and set a price target of ...

Buy Rating Affirmed for Delcath Systems Amid Strong Financial Results and Market Expansion

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Delcath Systems (DCTH – Research Report). The associated price target ...

Buy Rating Affirmed for Delcath Systems Amidst Strong Hepzato Launch and Promising Future Prospects

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Delcath Systems (DCTH – Research Report). The company'...

Delcath Systems (DCTH) Receives a Buy from Craig-Hallum

Delcath stock jumps 15% on Hepzato Kit study publication

Strong Buy Rating for Delcath Systems Supported by High Efficacy and Safety of CHEMOSAT Platform

The latest update is out from Delcath Systems (DCTH). Delcath Systems, Inc. has released a press release on August 28, 2024, announcing promising o...

Delcath Systems Reveals Encouraging Uveal Melanoma Study Results

BVNKF

BVNRY

FREY

IDYA

IMCR

JRNGF

NPWR

OBDC

OBDE

PACS

PAGS

REPYF

REPYY

Press Releases

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Delcath Systems

Delcath Systems (DCTH) Forecast

Delcath Systems (NASDAQ:DCTH) Stock, Quote.Headers.trade-ideas